Pernix Therapeutics Holdings Inc (NASDAQ:PTX), a specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2015. “Pernix had …
In a research report released Monday, Brean Capital analyst Difei Yang reiterated a Buy rating on shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) with …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the central patent for Zohydro® ER with BeadTek™, U.S.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), a specialty pharmaceutical company, today announced that a series of studies of ZX007, the Company’s next-generation extended release …
In a research report released today, Brean Capital analyst Difei Yang maintained a Buy rating on shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) with …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), a specialty pharmaceutical company, today announced the completion of a new three-year $50 million revolving credit facility with Wells …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), a specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2015. Second Quarter …
In a research report published yesterday, Brean Capital analyst Difei Yang reiterated a Buy rating on shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) with …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), a specialty pharmaceutical company, today announced positive results from Category 1 (in vitro) abuse deterrence studies with ZX007, utilizing …
In a research report issued today, Brean Capital analyst Difei Yang shared her expectations on Pernix Therapeutics Holdings Inc (NASDAQ:PTX), ahead of the company’s upcoming …
